PT-141 (Plerixafor) – 10MG

PT-141, also known as plerixafor, is a synthetic peptide originally developed for hematopoietic stem cell mobilization in clinical oncology research. This research-use-only peptide is provided in a 10mg formulation for laboratory-based studies related to its effects on cell mobilization and receptor interactions.

Research Context

PT-141 was initially approved by the FDA as a therapeutic agent for use in combination with granulocyte-colony stimulating factor (G-CSF) to increase the yield of hematopoietic stem and progenitor cells (HSPCs) for peripheral blood stem cell transplantation. Within the research community, it has been extensively studied for its mechanism of action, pharmacokinetics, and potential applications in cell-based therapies, though it is not intended for human or veterinary therapeutic use under normal circumstances.

Research Overview

PT-141 acts as a selective CXCR4 antagonist, binding to the CXCR4 receptor to disrupt its normal signaling pathways. In preclinical models, it has demonstrated utility in enhancing the mobilization of hematopoietic stem cells into the peripheral bloodstream, which is critical in procedures such as autologous stem cell transplantation. Research has also explored its potential as a tool for investigating stem cell dynamics, inflammation, and other physiological processes involving CXCR4-mediated interactions.

Key Research Focus Areas

• Hematopoietic Stem Cell Mobilization: Study of PT-141’s role in increasing HSPC yield for therapeutic applications.
• CXCR4 Receptor Biology: Investigation of PT-141’s antagonistic effects on CXCR4 signaling pathways.
• Stem Cell Dynamics: Exploration of PT-141’s impact on stem cell trafficking and engraftment.
• Pharmacological Profile: Characterization of its pharmacokinetic properties and metabolic clearance in laboratory settings.
• Potential Mechanistic Insights: Investigation of broader biological processes influenced by CXCR4 antagonism.

Important Safety and Compliance Notice

PT-141 is provided solely for laboratory and academic research purposes under the supervision of qualified professionals. The use of this peptide is restricted to in vitro, ex vivo, and controlled in vivo models and is not intended for any human, veterinary, or therapeutic applications. Researchers must adhere to all applicable regulatory guidelines, including but not limited to, institutional biosafety protocols, peer-reviewed experimental standards, and proper documentation of its use. Handling or administration of PT-141 outside of a licensed research environment is strictly prohibited and may constitute a violation of legal and ethical standards.

For research use only. Not for human or animal consumption.